https://scholars.lib.ntu.edu.tw/handle/123456789/537441
標題: | SF3B1 mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution | 作者: | CHIEN-CHIN LIN HSIN-AN HOU WEN-CHIEN CHOU Kuo Y.-Y. SHANG-JU WU Liu C.-Y. Chen, Chien-Yuan Tseng M.-H. Huang C.-F. Lee F.-Y. Liu M.-C. Liu C.-W. JIH-LUH TANG MING YAO SHANG-YI HUANG SZU-CHUN HSU BOR-SHENG KO WOEI TSAY YAO-CHANG CHEN HWEI-FANG TIEN |
公開日期: | 2014 | 出版社: | Wiley-Liss Inc. | 卷: | 89 | 期: | 8 | 起(迄)頁: | E109-E115 | 來源出版物: | American Journal of Hematology | 摘要: | The SF3B1 mutation can be detected in patients with myelodysplastic syndrome (MDS), but the report regarding the association of this mutation with other genetic alterations and its stability during disease progression is limited. In this study, SF3B1 mutations were identified in 10% of total cohort of 479 MDS patients and 61.8% of 34 patients with refractory anemia with ring sideroblasts (RARS). SF3B1 mutations were closely associated with older age, higher platelet counts, lower lactate dehydrogenase levels, good-risk cytogenetics, and mutations of DNMT3A, but inversely related to ASXL1 mutations. Most SF3B1-mutated patients had concurrent other genetic alterations, including DNMT3A and RUNX1 mutations. There was no prognostic difference between patients with SF3B1 mutations and those without. Sequential studies in 417 samples from 142 patients demonstrated that all SF3B1-mutated patients retained the same mutations during disease evolution with the exception of two patients who lost the mutation after allogeneic hematopoietic stem cell transplantation, whereas none of the SF3B1-wild patients acquired a novel mutation during clinical follow-ups. In conclusion, the patients with SF3B1 mutations had distinct clinic-biologic features. SF3B1 mutations, accompanied with other genetic alterations, especially DNMT3A mutations, may play a role in the development of MDS, but have little role in disease progression. Am. J. Hematol. 89:E109-E115, 2014. ? 2014 Wiley Periodicals, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904405761&doi=10.1002%2fajh.23734&partnerID=40&md5=f7fc8b068f139bf70b3334e8d2e3b722 https://scholars.lib.ntu.edu.tw/handle/123456789/537441 |
ISSN: | 0361-8609 | DOI: | 10.1002/ajh.23734 | SDG/關鍵字: | CD135 antigen; DNA methyltransferase 3A; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; Janus kinase 2; K ras protein; lactate dehydrogenase; mixed lineage leukemia protein; protein tyrosine phosphatase SHP 2; transcription factor EZH2; transcription factor RUNX1; WT1 protein; adolescent; adult; aged; allogeneic hematopoietic stem cell transplantation; article; clinical feature; cytogenetics; disease course; female; follow up; gene; gene mutation; human; karyotype; major clinical study; male; myelodysplastic syndrome; priority journal; prognosis; refractory anemia with ringed sideroblasts; SF3B1 gene; thrombocyte count; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Platelets; Core Binding Factor Alpha 2 Subunit; Disease Progression; DNA (Cytosine-5-)-Methyltransferase; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Mutation Rate; Myelodysplastic Syndromes; Phosphoproteins; Repressor Proteins; Ribonucleoprotein, U2 Small Nuclear |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。